bladder cancer

Overview

Bladder cancer (Wikidata: Q504775) is a malignancy arising from the urothelial cells that line the inner surface of the urinary bladder. It is one of the most common urologic cancers worldwide, representing a significant burden on public health systems due to its high incidence, frequent recurrence, and the substantial costs associated with long-term surveillance. The disease is broadly classified by depth of invasion: non-muscle invasive bladder cancer (NMIBC), which accounts for over 75% of all cases, and muscle-invasive bladder cancer (MIBC), which carries a markedly worse prognosis. The predominant histologic subtype is urothelial (transitional cell) carcinoma, though rarer variants exist. Molecularly, bladder cancer is characterized by considerable genomic heterogeneity, with frequent alterations in oncogenes such as FGFR3, tumor suppressor pathways, and epigenetic regulators. Key features driving its clinical challenge include a propensity for high recurrence after initial treatment, progression risk to muscle-invasive or metastatic disease, and an immunologically complex tumor microenvironment that influences both prognosis and response to therapy.

The standard diagnostic workup has historically relied on cystoscopy and urine cytology, both of which carry limitations in sensitivity and operator dependence, particularly for low-grade or flat lesions. Treatment strategies span intravesical therapies such as Bacillus Calmette-Guérin (BCG) for NMIBC, neoadjuvant cisplatin-based chemotherapy combined with radical cystectomy for MIBC, and—for advanced or metastatic disease—checkpoint inhibitor with agents such as pembrolizumab and nivolumab, as well as antibody-drug conjugates like enfortumab vedotin. The convergence of multi-omics profiling, nanotechnology-based drug delivery, artificial intelligence-assisted diagnostics, and next-generation immunotherapy has substantially accelerated the pace of discovery in this field.

Focus of Latest Publications

Recent literature reflects an intense focus on three interconnected axes in bladder cancer research: improving early and noninvasive diagnosis, elucidating the molecular and immune mechanisms of disease progression and therapy resistance, and expanding the armamentarium of therapeutic strategies.

Epidemiology, Staging, and Clinical Management

A 2026 review in Future Science OA (PMID 41661092) provided a comprehensive synthesis of diagnosis, evaluation, and management of NMIBC, underscoring that this subtype accounts for over 75% of bladder cancer cases globally and is associated with high recurrence rates and significant surveillance costs. The review highlighted ongoing challenges in balancing intensive follow-up with patient burden. Separately, an observational study drawing on the Surveillance, Epidemiology, and End Results (SEER) database (PMID 42175471) examined the impact of the COVID-19 pandemic in 2020 on the diagnosis, treatment, and cancer-specific survival of major urological cancers including bladder cancer, illustrating how system-level disruptions affect oncologic outcomes at a population level.

Neoadjuvant and Systemic Therapy

A pivotal 2026 ASCO educational review (PMID 41774881) established that neoadjuvant cisplatin-based chemotherapy—with or without immunotherapy—is the standard of care for muscle-invasive bladder cancer, with pathologic complete response (pCR) validated as a surrogate for survival after chemotherapy and a promising surrogate following other neoadjuvant treatments such as immunotherapy. Complementing this, a study in the World Journal of Urology (PMID 42132947) investigated chemotherapy-induced anemia as a prognostic factor for overall survival in bladder cancer patients treated with neoadjuvant cisplatin-based chemotherapy and cystectomy, identifying anemia as a clinically actionable marker in this setting. A transcriptome-based deep learning model (PMID 42055629) was developed and externally validated to predict gemcitabine and cisplatin chemotherapy response in urothelial carcinoma, acknowledging that response rates to this cornerstone regimen vary significantly among patients.

immunotherapy and the tumor microenvironment

Metastatic urothelial carcinoma has undergone a major therapeutic transition: a 2026 review in International Urology and Nephrology (PMID 42012774) documented the establishment of first-line immune checkpoint inhibitor-based combinations—including agents such as nivolumab and ipilimumab—as standard care, while also addressing the nuances of early versus deferred immunotherapy and post-progression survival. A real-world cohort study on immune checkpoint inhibitor-induced hyperthyroidism (PMID 42012269) noted that bladder cancer patients were less likely than renal cell carcinoma or endometrial cancer patients to develop this immune-related adverse event, offering clinically relevant comparative safety data. The combination of enfortumab vedotin plus pembrolizumab has emerged as a preferred first-line regimen for locally advanced or metastatic urothelial carcinoma, with a 2026 case report (PMID 42049426) documenting pathologic complete response after this combination in node-positive upper tract urothelial carcinoma.

Several studies illuminated mechanisms of resistance to checkpoint inhibitors. The ZNF737-CXCL10 axis was identified as a driver of immune exclusion and anti-PD-1 resistance in bladder cancer (PMID 41785601), while research on CCL5-high CD4+ T cells demonstrated their role in regulating macrophage polarization and promoting immunotherapy response (PMID 41706539), directly implicating CCL5/CCR1 signaling and the tumor microenvironment in determining sensitivity to checkpoint inhibitor. Work on CD44 and STAT3 imbalance (PMID 42049372) showed that cancer cell plasticity drives pembrolizumab resistance in urothelial carcinoma, linking stemness programs to immunotherapy failure. ALG1-mediated glycosylation of PD-L1 was shown to drive macrophage M2 polarization and promote bladder cancer progression (PMID 42168360), further underscoring the centrality of immune microenvironment remodeling. A broader review on nanomedicine in urinary system tumors (PMID 41947122) catalogued synergistic strategies coupling nanoparticle delivery with immunotherapy for bladder cancer, prostate cancer, and renal cell carcinoma.

Molecular Mechanisms, Biomarkers, and Resistance

FGFR3 oncogenic activation was shown to drive oxidative metabolic reprogramming in bladder cancer through a systems metabolomics approach (PMID 42177363), revealing a mechanistic link between a common oncogenic driver and metabolic vulnerability. Multi-omics analysis implicated TM4SF19 as a diagnostic and prognostic biomarker (PMID 42185687), while a toxicogenomics-informed study (PMID 42085381) integrated multi-omics and machine learning to examine bisphenol A-associated lactylation-related gene signatures. The role of HMGB3 in therapy resistance and cancer stemness was reviewed in the context of multiple malignancies including bladder cancer (PMID 41930588), with aberrant HMGB3 upregulation associated with poor prognosis. Research into PIKFYVE inhibitor resistance (PMID 41795291) found that targeting GRB2 with Polyphyllin H could overcome resistance by blocking the Akt-SREBP1-SCD1 pathway, while STEAP2-associated modulation of PI3K/AKT/mTOR signaling was linked to ginkgetin-induced apoptosis (PMID 42067902). Icariside II was shown to suppress bladder cancer progression via endoplasmic reticulum stress-mediated autophagy pathways and lysosomal dysfunction (PMID 42081993). Environmental exposure to acetyl tributyl citrate (ATBC) was investigated via multi-omics as a promoter of bladder cancer progression through the AKR1B1/epithelial-mesenchymal transition (EGFR/SRC-mediated EMT) axis (PMID 41846032).

Diagnostics: Liquid Biopsy, Biosensors, and Circulating Biomarkers

A 2026 review in Clinica Chimica Acta (PMID 41933678) synthesized emerging evidence for circulating biomarkers in bladder cancer, noting that conventional diagnosis and surveillance remain anchored in cystoscopy and urine cytology despite their invasiveness and limited sensitivity, and pointing toward liquid biopsy and molecular markers as the future of personalized management. A plasmon-enhanced magnetic fluorescent nanoprobe was developed for ultrasensitive detection of urinary miRNA-96, enabling early diagnosis and risk stratification (PMID 42130209). A self-assembled DNA nanoladder-based electrochemical biosensor permitted rapid and sensitive miRNA detection in urine (PMID 42045126). In vivo metabolic engineering of bladder cancer-derived extracellular vesicles was applied for noninvasive cancer detection (PMID 42090295). A one-step urinary extracellular vesicle capture-to-SERS platform using a temperature-responsive AuEIH substrate, analyzed with a transformer-based model, classified urologic cancers across clinical urine samples including bladder, prostate, and renal cancer (PMID 41964667). A 2026 Biosensors review (PMID 41892063) catalogued noninvasive urine-based diagnostic technologies for early bladder cancer, spanning DNA methylation profiling, protein and RNA biomarkers, and nanosensor platforms.

Novel Drug Delivery and Intravesical Strategies

Given high recurrence rates and limited long-term efficacy of current intravesical therapies, multiple groups explored advanced local delivery systems. Intravesical delivery of p21 mRNA-loaded lipid nanoparticles was evaluated as a tumor suppressor replacement therapy (PMID 42144924). Squid tentacle-mimetic magnetically targeted nanomotors were engineered to overcome the bladder's mucus barrier for synergistic chemotherapy-immunotherapy (PMID 41839262). Nanomotor-assisted intravesical chemotherapy was shown to reduce tumor burden and suppress early regrowth (PMID 42024786). A light-activated targeted degradation strategy employing a VHL-targeting drug was proposed as a precision therapy approach for bladder cancer (PMID 41785828). prostaglandin E2 modulation and photochemotherapy were among additional strategies referenced in the broader therapeutic landscape.

Key Publications

• Jun Artificial intelligence-assisted urine cytology based on the Paris System for Reporting Urothelial Carcinoma. (Cancer cytopathology, 2026, PMID 42223163): "Urine cytology is a noninvasive and valuable tool for detecting urothelial carcinoma but suffers from variable sensitivity and observer dependency."
• Jun Intravesical Delivery of P21 mRNA-Loaded Lipid Nanoparticles as a Tumor Suppressor Replacement Therapy for Bladder Cancer. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 42144924): "Bladder cancer is characterized by high recurrence rates and limited long-term benefit from current intravesical therapies, highlighting the need for alternative localized treatment strategies."
• May Icariside II suppresses bladder cancer progression via endoplasmic reticulum stress-mediated autophagy and lysosomal dysfunction. (European journal of pharmacology, 2026, PMID 42081993): "However, the specific mechanism underlying its anticancer activity in bladder cancer remains unclear."
• May Multi-omics analysis reveals TM4SF19 as a diagnostic and prognostic biomarker in bladder cancer. (Discover oncology, 2026, PMID 42185687): "Bladder cancer poses a significant clinical challenge due to its high recurrence and heterogeneity, necessitating novel biomarkers."
• May Plasmon-Enhanced Magnetic Fluorescent Nanoprobe for Ultrasensitive Detection of Urinary miRNA-96 Enabling Early Diagnosis and Risk Stratification of Bladder Cancer. (Analytical chemistry, 2026, PMID 42130209): "Bladder cancer (BC) represents a major threat to urinary tract health, and its early detection is critically associated with improved patient survival and clinical outcomes."
• May FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach. (Communications biology, 2026, PMID 42177363): "Bladder cancer is one of the most common malignancies worldwide, impacting public health systems due to its high rate of recurrence."
• May The impact of the COVID-19 pandemic in 2020 on the diagnosis, treatment, and cancer-specific survival of major urological cancers: An observational study. (Medicine, 2026, PMID 42175471): "Patients diagnosed with prostate cancer, bladder cancer, and kidney cancer were identified from the Surveillance, Epidemiology, and End Results (SEER) database."
• May ALG1-mediated PDL1 glycosylation drives macrophage m2 polarization to promote bladder cancer progression. (Cell death and differentiation, 2026, PMID 42168360): "While its role in congenital glycosylation disorders is well established, the contribution of ALG1 to bladder cancer (BC) progression, particularly its impact on the tumor immune microenvironment, remains poorly understood."
• May In Vivo Metabolic Engineering of Bladder Cancer-Derived Extracellular Vesicles for Noninvasive Cancer Detection. (Journal of the American Chemical Society, 2026, PMID 42090295): "Early and precise diagnosis of bladder cancer (BC) is crucial for improving patient prognosis."
• May Multi-omics analysis and preliminary experimental validation of acetyl tributyl citrate (ATBC) promoting bladder cancer progression via the AKR1B1/EMT axis. (Environmental pollution (Barking, Essex : 1987), 2026, PMID 41846032): "However, its toxicological impact on bladder cancer (BCa) remains unclear."